Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$134.67 +0.4%	$130.38	$110.86 ▼ $141.23	$233.52B	0.69	4.73 million shs	5.89 million shs
LLY Eli Lilly and Company	$762.84 +0.4%	$739.17	$623.78 ▼ $939.86	$719.43B	0.47	3.19 million shs	3.46 million shs
MRK Merck & Co., Inc.	$81.60 +0.6%	$82.83	$73.31 ▼ $119.20	$202.67B	0.37	11.20 million shs	10.45 million shs
NVO Novo Nordisk A/S	$61.86 +6.3%	$57.03	$45.05 ▼ $135.20	$259.86B	0.66	12.76 million shs	24.54 million shs
PFE Pfizer	$24.16 +0.4%	$24.67	$20.92 ▼ $30.43	$136.74B	0.55	40.03 million shs	34.23 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.58%	+1.59%	+2.65%	+1.35%	+17.24%
LLY Eli Lilly and Company	+0.32%	+0.92%	+8.42%	-0.08%	-15.72%
MRK Merck & Co., Inc.	+0.60%	-4.12%	-3.98%	+2.97%	-31.24%
NVO Novo Nordisk A/S	+6.30%	+13.95%	+13.01%	-16.13%	-53.17%
PFE Pfizer	+0.52%	-2.76%	-4.51%	+0.78%	-18.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$134.67 +0.4%	$130.38	$110.86 ▼ $141.23	$233.52B	0.69	4.73 million shs	5.89 million shs
LLY Eli Lilly and Company	$762.84 +0.4%	$739.17	$623.78 ▼ $939.86	$719.43B	0.47	3.19 million shs	3.46 million shs
MRK Merck & Co., Inc.	$81.60 +0.6%	$82.83	$73.31 ▼ $119.20	$202.67B	0.37	11.20 million shs	10.45 million shs
NVO Novo Nordisk A/S	$61.86 +6.3%	$57.03	$45.05 ▼ $135.20	$259.86B	0.66	12.76 million shs	24.54 million shs
PFE Pfizer	$24.16 +0.4%	$24.67	$20.92 ▼ $30.43	$136.74B	0.55	40.03 million shs	34.23 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.58%	+1.59%	+2.65%	+1.35%	+17.24%
LLY Eli Lilly and Company	+0.32%	+0.92%	+8.42%	-0.08%	-15.72%
MRK Merck & Co., Inc.	+0.60%	-4.12%	-3.98%	+2.97%	-31.24%
NVO Novo Nordisk A/S	+6.30%	+13.95%	+13.01%	-16.13%	-53.17%
PFE Pfizer	+0.52%	-2.76%	-4.51%	+0.78%	-18.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.91	Moderate Buy	$144.47	7.28% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$939.61	23.17% Upside
MRK Merck & Co., Inc.	2.33	Hold	$106.41	30.41% Upside
NVO Novo Nordisk A/S	2.37	Hold	$81.00	30.93% Upside
PFE Pfizer	2.39	Hold	$28.12	16.41% Upside

Current Analyst Ratings Breakdown

Latest PFE, LLY, NVO, ABT, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2025	LLY Eli Lilly and Company	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$970.00 ➝ $830.00
9/17/2025	MRK Merck & Co., Inc.	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $90.00
9/17/2025	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/16/2025	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,100.00 ➝ $1,050.00
9/16/2025	NVO Novo Nordisk A/S	Rothschild Redb Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/16/2025	NVO Novo Nordisk A/S	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/9/2025	NVO Novo Nordisk A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.59	$6.61 per share	20.38	$27.62 per share	4.88
LLY Eli Lilly and Company	$45.04B	16.03	$14.29 per share	53.40	$15.03 per share	50.75
MRK Merck & Co., Inc.	$63.62B	3.20	$9.52 per share	8.57	$18.33 per share	4.45
NVO Novo Nordisk A/S	$42.12B	6.56	$4.15 per share	14.92	$4.66 per share	13.28
PFE Pfizer	$63.63B	2.16	$4.38 per share	5.51	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.88	23.50	2.54	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	49.86	24.51	1.06	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.57	8.24	0.83	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	17.00	13.28	2.21	35.60%	78.64%	24.51%	11/5/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	12.85	7.97	0.85	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest PFE, LLY, NVO, ABT, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/15/2025	Q3 2025	ABT Abbott Laboratories	$1.30	N/A	N/A	N/A	$11.40 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.75%	N/A	29.57%	54 Years
LLY Eli Lilly and Company	$6.00	0.79%	N/A	39.22%	11 Years
MRK Merck & Co., Inc.	$3.24	3.97%	N/A	49.92%	14 Years
NVO Novo Nordisk A/S	$0.82	1.33%	N/A	22.53%	N/A
PFE Pfizer	$1.72	7.12%	N/A	91.49%	16 Years

Latest PFE, LLY, NVO, ABT, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
LLY Eli Lilly and Company	1.86	1.28	1.00
MRK Merck & Co., Inc.	0.69	1.42	1.17
NVO Novo Nordisk A/S	0.52	0.78	0.56
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.49 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, LLY, NVO, ABT, and MRK Headlines

Recent News About These Companies

Pfizer: Dividend Cushion Ratio Brings Yield Sustainability Into Question

September 18 at 4:31 PM | seekingalpha.com

Arvinas amends collaboration with Pfizer

September 18 at 10:31 AM | thepharmaletter.comT

Exchange Traded Concepts LLC Boosts Position in Pfizer Inc. $PFE

September 18 at 7:44 AM | marketbeat.com

Fulton Bank N.A. Buys 19,852 Shares of Pfizer Inc. $PFE

September 18 at 7:23 AM | marketbeat.com

Cypress Point Wealth Management LLC Takes Position in Pfizer Inc. $PFE

September 18 at 7:13 AM | marketbeat.com

Mn Services Vermogensbeheer B.V. Acquires 51,900 Shares of Pfizer Inc. $PFE

September 18 at 6:37 AM | marketbeat.com

Baader Bank Aktiengesellschaft Increases Stake in Pfizer Inc. $PFE

September 18 at 6:02 AM | marketbeat.com

Sumitomo Mitsui DS Asset Management Company Ltd Raises Stock Position in Pfizer Inc. $PFE

September 18 at 5:52 AM | marketbeat.com

Procyon Advisors LLC Has $1.42 Million Stock Position in Pfizer Inc. $PFE

September 18 at 4:39 AM | marketbeat.com

Roivant and Pfizer-backed Priovant post late-stage trial win for dermatomyositis therapy

September 17 at 7:28 PM | msn.com

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

September 17 at 5:50 PM | reuters.com

Pfizer: Cheap Doesn't Mean Good

September 17 at 1:10 PM | seekingalpha.com

Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

September 17 at 7:05 AM | marketbeat.com

Pfizer Inc. $PFE Shares Acquired by Sunpointe LLC

September 17 at 6:14 AM | marketbeat.com

Mirador Capital Partners LP Buys 11,662 Shares of Pfizer Inc. $PFE

September 17 at 5:45 AM | marketbeat.com

Gateway Investment Advisers LLC Buys 66,491 Shares of Pfizer Inc. $PFE

September 17 at 5:44 AM | marketbeat.com

Westbourne Investments Inc. Cuts Position in Pfizer Inc. $PFE

September 17 at 5:27 AM | marketbeat.com

Financiere des Professionnels Fonds d investissement inc. Has $10.36 Million Stake in Pfizer Inc. $PFE

September 17 at 5:19 AM | marketbeat.com

Pfizer Inc. $PFE Shares Bought by Krilogy Financial LLC

September 17 at 4:36 AM | marketbeat.com

Fiduciary Alliance LLC Acquires 89,635 Shares of Pfizer Inc. $PFE

September 17 at 4:27 AM | marketbeat.com

NBC Securities Inc. Decreases Stock Holdings in Pfizer Inc. $PFE

September 17 at 3:56 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, LLY, NVO, ABT, and MRK Company Descriptions

Abbott Laboratories NYSE:ABT

$134.67 +0.50 (+0.37%)

Closing price 09/18/2025 03:59 PM Eastern

Extended Trading

$133.95 -0.72 (-0.54%)

As of 09/18/2025 07:48 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$762.84 +2.71 (+0.36%)

Closing price 09/18/2025 03:59 PM Eastern

Extended Trading

$761.06 -1.78 (-0.23%)

As of 09/18/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$81.60 +0.46 (+0.57%)

Closing price 09/18/2025 03:59 PM Eastern

Extended Trading

$81.67 +0.07 (+0.08%)

As of 09/18/2025 08:00 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$61.86 +3.66 (+6.30%)

Closing price 09/18/2025 03:59 PM Eastern

Extended Trading

$61.94 +0.08 (+0.12%)

As of 09/18/2025 08:00 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$24.16 +0.11 (+0.44%)

Closing price 09/18/2025 03:59 PM Eastern

Extended Trading

$24.19 +0.04 (+0.14%)

As of 09/18/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, LLY, NVO, ABT, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, LLY, NVO, ABT, and MRK Earnings

Compare Dividends

Latest PFE, LLY, NVO, ABT, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, LLY, NVO, ABT, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, LLY, NVO, ABT, and MRK Company Descriptions

Abbott Laboratories NYSE:ABT

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools